CNTX stock icon

Context Therapeutics
CNTX

$2.17
6.93%
 

About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Employees: 9

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

35% more capital invested

Capital invested by funds: $4.02M [Q4 2023] → $5.43M (+$1.41M) [Q1 2024]

9% more funds holding

Funds holding: 23 [Q4 2023] → 25 (+2) [Q1 2024]

2.36% more ownership

Funds ownership: 22.28% [Q4 2023] → 24.64% (+2.36%) [Q1 2024]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
84%
upside
Avg. target
$5.88
171%
upside
High target
$10
361%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Joseph Catanzaro
107%upside
$4.5
Overweight
Initiated
16 May 2024
HC Wainwright & Co.
Emily Bodnar
130%upside
$5
Buy
Maintained
9 May 2024
Maxim Group
Jason McCarthy
361%upside
$10
Buy
Maintained
9 May 2024
HC Wainwright & Co.
Emily Bodnar
84%upside
$4
Buy
Maintained
21 Mar 2024

Financial journalist opinion